Ryan, Meagan B.
Corcoran, Ryan B.
Article History
First Online: 1 October 2018
Competing interests
: R.B.C. has received consulting fees from Amgen, Astex, Avidity, Bristol-Myers Squibb, FOG Pharma, Genentech, LOXO, Merrimack, N-of-One, Roche, Roivant, Shire, Symphogen, Taiho and Warp Drive Bio, as well as research support from AstraZeneca and Sanofi. M.B.R. declares no competing interest.